mescreen™ gives employers a premium, optional wellbeing benefit built around at-home mitochondrial function testing, practical mitochondrial function reporting and clearer conversations about energy, recovery and long-term health.
An employee health perk should be easy to understand, voluntary and useful after the campaign email has been forgotten. mescreen™ is designed for UK teams that want a more credible benefit than merchandise, step challenges or low-use wellness subscriptions.
The mescreen™ mitochondrial function test costs £599 and can be offered as a funded, subsidised or leadership-level benefit. Staff complete the sample pathway at home, then receive a report that explains cellular-energy and biomarker themes in plain language. The right positioning is preventative and educational: it helps people ask better questions about recovery, metabolic health and resilience, while keeping diagnosis and treatment decisions with qualified clinicians.
mescreen™ works best when employers frame it as an optional personal insight benefit, not a staff surveillance tool or a substitute for GP care.
Staff receive a structured report they can keep, revisit and discuss with an appropriate professional if they want clinical interpretation.
Individual results should remain private to the employee. Employers can support access and education without viewing personal reports.
UK wellbeing spend is easier to defend when the benefit has a defined experience, a concrete report and cautious medical boundaries.
The strongest employee-benefit use is selective and well explained: leadership groups, retention packages, wellbeing weeks, high-performance teams or staff cohorts who want more than a general lifestyle nudge.
According to the Office for National Statistics, the UK sickness absence rate was 2.6% in 2022, with minor illness, musculoskeletal issues and mental health among leading reasons for lost work time. mescreen™ does not solve those categories, but it gives staff a more structured way to explore health signals that may influence energy and recovery conversations.
Employers should avoid using the test to assess fitness for work, decide adjustments, rank staff health or replace occupational-health advice. Employees with symptoms or concerns should use NHS or private medical care.
A credible health perk should be specific enough to be useful and careful enough not to overstep. mescreen™’s role is to support education and report-led insight, not to diagnose staff or promise productivity gains.
Quotable summary: mescreen™ is best understood as an optional employee health insight benefit, not an occupational-health assessment. It can help staff understand cellular-energy themes while keeping medical decisions with clinicians.
Sources referenced for workplace context: CIPD Health and wellbeing at work and ONS sickness absence in the labour market, 2022.
mescreen™ gives staff an optional at-home mitochondrial function test and report-led biomarker context, rather than a discount, challenge or general wellbeing subscription.
No. Individual results should remain private to the employee. Any employer discussion should be limited to programme logistics or, where agreed, aggregated non-identifying themes.
No. mescreen™ is a wellness and functional laboratory assessment. It does not diagnose burnout, fatigue syndromes, metabolic disease or any medical condition, and it does not replace NHS or private medical care.
It is best suited to UK teams, leadership groups and benefits programmes where staff value prevention, recovery, healthspan and practical data over generic wellness rewards.
Staff with symptoms, urgent concerns or abnormal findings should speak with their GP, NHS 111, urgent care or emergency services as appropriate. mescreen™ can support context but not emergency care or diagnosis.
Use mescreen™ for staff who want a premium, evidence-aware health benefit and a practical report they can take forward responsibly.